Mirum Pharmaceuticals Reports Positive Phase 3 Results for LIVMARLI

Key Facts

1Mirum Pharmaceuticals revealed the results of its Phase 3 study for the drug LIVMARLI.

Mirum Pharmaceuticals revealed the results of its Phase 3 study for the drug LIVMARLI. Reuters reported that the company released clinical data regarding this key asset in its developmental pipeline.

The company is advancing its clinical development program to expand the indications or confirm the efficacy of LIVMARLI. These Phase 3 outcomes represent a critical milestone for the biotechnology firm as it seeks to validate its core clinical assets.